Table 4.
Base-case results [Chinese yuan (¥) and USD ($)] by treatment
| Treatment | Total costs | Total life-years | Total QALYs | Incremental costs | Incremental QALYs | ICER |
|---|---|---|---|---|---|---|
| Teriflunomide 14 mg | ¥1,887,144 ($283,884) | 20.28 | 9.60 | − ¥174,249 (− $26,212) | 0.73 | Dominant |
| Disease-relateda | ¥758,765 ($114,141) | NA | 9.60 | − ¥36,144 (− $5,437) | 0.68 | |
| Treatment-relatedb | ¥1,126,796 ($169,504) | NA | NA | − ¥136,104 (− $20,474) | NA | |
| AEs | ¥1583 ($238) | NA | − 0.00005 | − ¥2001 (− $301) | 0.04185 | |
| Interferon beta-1b | ¥2,061,393 ($310,096) | 20.11 | 8.88 | Reference | Reference | Reference |
| Disease-relateda | ¥794,909 ($119,578) | NA | 8.92 | |||
| Treatment-relatedb | ¥1,262,900 ($189,978) | NA | NA | |||
| AEs | ¥3584 ($539) | NA | − 0.0419 |
Average exchange rate for 2018 of US$1 = ¥6.6476 was used for conversion
ICER incremental cost-effectiveness ratio, Incr. incremental, NA not applicable, QALY quality-adjusted life-year
aCosts and QALYs due to disability and relapses
bTreatment acquisition cost, administration cost, and monitoring cost